Apixaban: Uses, Dosage & Side Effects
Direct oral anticoagulant (DOAC) – selective factor Xa inhibitor for stroke prevention and blood clot treatment
Quick facts about Apixaban
Key Takeaways
- Apixaban is a direct oral anticoagulant (DOAC) that prevents blood clots by selectively blocking factor Xa in the coagulation cascade.
- The ARISTOTLE trial demonstrated apixaban to be superior to warfarin for stroke prevention in atrial fibrillation, with lower rates of bleeding and mortality.
- Unlike warfarin, apixaban does not require routine INR blood monitoring, has fewer food interactions, and has a predictable dose-response relationship.
- The standard dose is 5 mg twice daily, with a reduced dose of 2.5 mg twice daily for patients meeting specific criteria (age ≥80, weight ≤60 kg, or creatinine ≥133 µmol/L).
- Andexanet alfa is an approved specific reversal agent for apixaban in cases of life-threatening bleeding.
What Is Apixaban and What Is It Used For?
Quick Answer: Apixaban is a direct oral anticoagulant (DOAC) that belongs to the class of factor Xa inhibitors. It is used to prevent stroke in atrial fibrillation, treat deep vein thrombosis and pulmonary embolism, and prevent blood clots after hip or knee replacement surgery.
Apixaban is a prescription anticoagulant medication that works by selectively and reversibly inhibiting factor Xa, a critical enzyme in the blood coagulation cascade. Factor Xa occupies a central position where the intrinsic and extrinsic coagulation pathways converge, making it an effective target for anticoagulation therapy. By blocking factor Xa, apixaban reduces the generation of thrombin, which in turn reduces the formation of blood clots (thrombi).
Originally developed by Bristol-Myers Squibb and Pfizer and marketed under the brand name Eliquis, apixaban has become one of the most commonly prescribed anticoagulants worldwide since its approval by the European Medicines Agency (EMA) in 2011 and the U.S. Food and Drug Administration (FDA) in 2012. Multiple generic versions are now available, including Apixaban Sandoz, Apixaban Grindeks, Apixaban Reddy, Apixaban Krka, Apixaban Viatris, Apixaban Vivanta, Apixaban STADA, and Apixaban Accord.
Apixaban belongs to a family of medications known as direct oral anticoagulants (DOACs), sometimes referred to as novel oral anticoagulants (NOACs). This group also includes rivaroxaban, edoxaban, and dabigatran. DOACs have largely replaced warfarin as the first-line oral anticoagulant for many conditions due to their more predictable pharmacology and improved safety profile.
Approved Indications
Apixaban is approved for the following clinical indications across major regulatory agencies (EMA, FDA, and other national authorities):
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) who have one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75, hypertension, diabetes mellitus, or symptomatic heart failure.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults.
- Prevention of recurrent DVT and PE in adults who have completed at least 6 months of anticoagulation therapy.
- Prevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery.
The European Society of Cardiology (ESC) 2024 guidelines recommend DOACs, including apixaban, as the preferred oral anticoagulants over warfarin for stroke prevention in patients with atrial fibrillation, except in patients with mechanical heart valves or moderate-to-severe mitral stenosis.
Mechanism of Action
Apixaban is a potent, oral, reversible, direct and highly selective active-site inhibitor of factor Xa. It does not require antithrombin III for its anticoagulant activity, which distinguishes it from heparin-based anticoagulants. Apixaban inhibits both free and clot-bound factor Xa, as well as prothrombinase activity. By inhibiting factor Xa, it decreases thrombin generation and thrombus development without directly affecting existing clots. This mechanism provides effective anticoagulation while maintaining a more predictable pharmacological profile than vitamin K antagonists like warfarin.
What Should You Know Before Taking Apixaban?
Quick Answer: Before starting apixaban, your doctor will assess your kidney and liver function, bleeding risk, and other medications. Apixaban is contraindicated in active clinically significant bleeding, severe liver disease, and in patients with prosthetic heart valves. Special dose adjustments are needed for certain patient groups.
Before prescribing apixaban, your healthcare provider will conduct a thorough assessment of your medical history, current medications, and overall health status. This evaluation is essential to ensure that apixaban is safe and appropriate for your specific situation. Anticoagulant therapy always involves balancing the benefit of preventing blood clots against the risk of bleeding, and several factors can influence this balance.
Contraindications
Apixaban should not be used in the following situations:
- Active clinically significant bleeding: Patients with ongoing haemorrhage from any site, including gastrointestinal, intracranial, or urogenital bleeding.
- Hypersensitivity: Known allergy to apixaban or any of the excipients in the formulation.
- Severe hepatic disease: Liver disease associated with coagulopathy and clinically relevant bleeding risk, including cirrhosis classified as Child-Pugh C.
- Lesions at risk of clinically significant bleeding: Such as current or recent gastrointestinal ulceration, malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, or oesophageal varices.
- Prosthetic heart valves: Apixaban has not been studied and is not recommended for patients with mechanical heart valves requiring anticoagulation. Warfarin remains the standard treatment for this population.
Premature discontinuation of apixaban without switching to an alternative anticoagulant increases the risk of thrombotic events, including stroke. If you need to stop apixaban for surgery or other reasons, your doctor will provide specific guidance on when to stop and restart the medication. Never stop taking apixaban without consulting your prescriber.
Warnings and Precautions
Special caution is required when using apixaban in the following situations:
- Increased bleeding risk: Conditions that increase bleeding risk include uncontrolled severe arterial hypertension, vascular retinopathy, recent biopsy or major trauma, active peptic ulcer disease, bacterial endocarditis, or thrombocytopenia. Concomitant use of antiplatelet agents or other anticoagulants further increases this risk.
- Renal impairment: Apixaban can be used in mild to moderate renal impairment without dose adjustment for most indications. However, in patients with creatinine clearance 15–29 mL/min, it should be used with caution, and in patients with creatinine clearance below 15 mL/min or on dialysis, clinical data are limited and apixaban is not recommended.
- Hepatic impairment: Apixaban can be used with caution in mild hepatic impairment (Child-Pugh A). It should be used with caution in moderate hepatic impairment (Child-Pugh B). It is contraindicated in severe hepatic impairment (Child-Pugh C).
- Spinal or epidural anaesthesia: Patients receiving neuraxial anaesthesia or undergoing spinal/epidural puncture are at risk of developing epidural or spinal haematoma, which may result in long-term or permanent paralysis. Specific timing guidelines for discontinuation and reinitiation around these procedures must be followed.
- Hip fracture surgery: Apixaban has not been studied in patients undergoing hip fracture surgery and is therefore not recommended in this population.
Pregnancy and Breastfeeding
There are limited data on the use of apixaban during pregnancy. Animal studies have not shown direct or indirect harmful effects with respect to reproductive toxicity. However, as a precautionary measure, apixaban is not recommended during pregnancy. Women of childbearing potential should discuss contraception with their doctor while taking apixaban.
It is not known whether apixaban or its metabolites are excreted in human breast milk. Animal studies have shown that apixaban is present in breast milk. A risk to the breastfed child cannot be excluded. Therefore, a decision must be made whether to discontinue breastfeeding or to discontinue apixaban therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
No dose adjustment is needed based on gender, race, or ethnicity. For elderly patients (age ≥80), body weight (≤60 kg), or renal impairment (serum creatinine ≥133 µmol/L or 1.5 mg/dL), a dose reduction to 2.5 mg twice daily is recommended when at least two of these three factors are present in patients being treated for atrial fibrillation.
How Does Apixaban Interact with Other Drugs?
Quick Answer: Apixaban is metabolised primarily by CYP3A4 and is a substrate for P-glycoprotein (P-gp). Strong dual inhibitors of CYP3A4 and P-gp (such as ketoconazole and ritonavir) significantly increase apixaban levels, while strong dual inducers (such as rifampicin and phenytoin) significantly decrease them. Concomitant use of other anticoagulants, antiplatelet agents, and NSAIDs increases bleeding risk.
Drug interactions are an important consideration with apixaban, although it has fewer clinically significant interactions than warfarin. Apixaban is metabolised primarily by the cytochrome P450 enzyme CYP3A4, with minor contributions from CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2J2. It is also a substrate for the drug efflux transporter P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Drugs that affect these pathways can alter apixaban plasma levels and potentially change its efficacy or safety profile.
It is critical to inform your prescriber about all medications you are taking, including over-the-counter medicines, herbal supplements, and vitamins. While apixaban has fewer interactions than warfarin, certain combinations can be dangerous and may require dose adjustments or alternative therapy.
Major Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Ketoconazole, itraconazole, voriconazole, posaconazole | Strong CYP3A4 and P-gp inhibitors; significantly increase apixaban plasma levels (approximately 2-fold) | Reduce apixaban dose by 50% (i.e. 2.5 mg twice daily instead of 5 mg) or avoid combination if already on reduced dose |
| HIV protease inhibitors (ritonavir, nelfinavir) | Strong CYP3A4 and P-gp inhibitors; significantly increase apixaban levels | Reduce apixaban dose by 50% or avoid combination |
| Rifampicin | Strong CYP3A4 and P-gp inducer; decreases apixaban levels by approximately 54% | Avoid concomitant use; apixaban efficacy is substantially reduced |
| Phenytoin, carbamazepine, phenobarbital | Strong CYP3A4 inducers; expected to significantly decrease apixaban levels | Avoid concomitant use |
| St John’s Wort (Hypericum perforatum) | Strong CYP3A4 inducer; expected to decrease apixaban levels | Avoid concomitant use |
| Other anticoagulants (heparin, warfarin, enoxaparin) | Additive anticoagulant effect; markedly increased bleeding risk | Avoid concomitant use except during transition between agents |
Minor Interactions
| Interacting Drug | Effect | Clinical Recommendation |
|---|---|---|
| Diltiazem | Moderate CYP3A4 and P-gp inhibitor; increases apixaban levels by approximately 40% | No dose adjustment needed; use with caution |
| Naproxen, ibuprofen, diclofenac (NSAIDs) | Do not alter apixaban levels but independently increase bleeding risk, particularly gastrointestinal | Use with caution; avoid long-term concomitant use if possible |
| Aspirin (low dose) | Increases bleeding risk through additional antiplatelet effect | Use only when clinically indicated (e.g. recent acute coronary syndrome); shortest duration possible |
| Clopidogrel, ticagrelor, prasugrel | Antiplatelet agents; additive bleeding risk | Use only when clinically indicated; monitor for signs of bleeding |
| SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine) | May impair platelet function and increase bleeding risk | Use with caution; monitor for unusual bleeding |
Unlike warfarin, apixaban does not have significant interactions with vitamin K-containing foods. You do not need to restrict your intake of green leafy vegetables, broccoli, or other vitamin K-rich foods. Apixaban can be taken with or without food. Grapefruit juice has a minimal effect on apixaban levels and does not require dose adjustment.
What Is the Correct Dosage of Apixaban?
Quick Answer: The standard dose of apixaban varies by indication. For atrial fibrillation, the usual dose is 5 mg twice daily. A reduced dose of 2.5 mg twice daily is used for specific patient groups and for VTE prevention after surgery. Apixaban should be taken approximately 12 hours apart, with or without food.
Apixaban dosing is straightforward compared to warfarin, as it uses fixed doses without the need for individualised titration based on blood tests. However, the correct dose depends on the indication being treated and certain patient characteristics. It is essential to take the dose prescribed by your doctor and not to adjust it yourself.
Adults
| Indication | Standard Dose | Reduced Dose | Duration |
|---|---|---|---|
| Stroke prevention in atrial fibrillation | 5 mg twice daily | 2.5 mg twice daily* | Long-term (indefinite) |
| Treatment of DVT/PE | 10 mg twice daily for 7 days, then 5 mg twice daily | Not applicable | At least 3–6 months |
| Prevention of recurrent DVT/PE | 2.5 mg twice daily | Not applicable | Extended (decision based on individual risk-benefit) |
| VTE prevention after hip replacement | 2.5 mg twice daily (starting 12–24 hours post-surgery) | Not applicable | 32–38 days |
| VTE prevention after knee replacement | 2.5 mg twice daily (starting 12–24 hours post-surgery) | Not applicable | 10–14 days |
*Dose reduction criteria for atrial fibrillation: A reduced dose of 2.5 mg twice daily is recommended for patients with at least two of the following three characteristics: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥133 µmol/L (1.5 mg/dL). This dose reduction is based on pharmacokinetic modelling and the ARISTOTLE trial subgroup analyses.
Children
Apixaban is not approved for use in children under 18 years of age. The safety and efficacy of apixaban in the paediatric population have not been established. Alternative anticoagulants (typically heparin-based) are used in paediatric patients who require anticoagulation.
Elderly
No general dose adjustment is required solely based on age. However, elderly patients may have reduced renal function and lower body weight, which may qualify them for the reduced dose criteria described above. The ARISTOTLE trial included a substantial proportion of patients aged 75 and older, demonstrating that apixaban maintained its favourable efficacy and safety profile in this population. Elderly patients should be regularly assessed for changes in renal function and bleeding risk.
Missed Dose
If you miss a dose of apixaban, take it as soon as you remember on the same day. Then continue with the regular twice-daily dosing schedule. Do not take a double dose to compensate for a missed dose. If it is almost time for your next scheduled dose, skip the missed dose and take the next dose at the normal time. Missing doses increases the risk of blood clots, so it is important to take apixaban as consistently as possible.
Overdose
There is no specific antidote for apixaban overdose in the outpatient setting, although andexanet alfa may be used in hospital for life-threatening bleeding. In case of overdose, seek immediate medical attention. The use of activated charcoal within 2–6 hours of ingestion may reduce absorption. Apixaban is not expected to be dialysable due to its high protein binding (approximately 87%). Treatment of overdose is primarily supportive, with management of bleeding complications as they arise. Prothrombin complex concentrates (PCCs) may be considered if bleeding is severe and andexanet alfa is unavailable.
If you suspect an overdose of apixaban, contact your local poison control centre or go to the nearest emergency department immediately. Symptoms of overdose may include unusual bleeding, blood in urine or stool, excessive bruising, or prolonged bleeding from cuts. Do not attempt to induce vomiting unless instructed by a healthcare professional.
What Are the Side Effects of Apixaban?
Quick Answer: The most common side effects of apixaban are bleeding-related, including nosebleeds, bruising, and blood in the urine. Serious side effects include major bleeding events such as gastrointestinal haemorrhage and intracranial bleeding. Apixaban has a lower rate of major bleeding compared to warfarin.
As with all anticoagulant medications, the most significant risk associated with apixaban is bleeding. The ARISTOTLE trial, which compared apixaban with warfarin in over 18,000 patients with atrial fibrillation, demonstrated that apixaban had a significantly lower rate of major bleeding (2.13% per year vs. 3.09% per year with warfarin, p < 0.001). The rate of intracranial haemorrhage was also substantially lower with apixaban compared to warfarin (0.33% vs. 0.80% per year).
However, all patients taking apixaban should be aware of the signs and symptoms of bleeding and know when to seek medical attention. The following side effects are classified by frequency based on clinical trial data and post-marketing surveillance.
Common
Affects 1–10 in 100 patients
- Epistaxis (nosebleeds)
- Bruising (ecchymosis, skin contusion)
- Haematuria (blood in urine)
- Haematoma (collection of blood under the skin)
- Gingival bleeding (bleeding gums)
- Gastrointestinal haemorrhage (bleeding in the stomach or intestines)
- Anaemia (reduced haemoglobin levels)
- Nausea
Uncommon
Affects 1–10 in 1,000 patients
- Rectal bleeding
- Haemoptysis (coughing up blood)
- Haemorrhoidal bleeding
- Mouth bleeding
- Vaginal bleeding (abnormal)
- Blood in stool (haematochezia)
- Muscle haemorrhage
- Eye haemorrhage (conjunctival, retinal)
- Hypotension (low blood pressure)
- Allergic reactions (pruritus, skin rash)
- Elevated liver enzymes (ALT, AST, GGT)
Rare
Affects 1–10 in 10,000 patients
- Intracranial haemorrhage (bleeding in the brain)
- Retroperitoneal haemorrhage
- Intraocular haemorrhage
- Surgical site haemorrhage
- Hypersensitivity reactions (angioedema, allergic oedema)
Very Rare / Post-marketing Reports
Affects fewer than 1 in 10,000 patients
- Anaphylactic reactions
- Stevens-Johnson syndrome
- Severe or uncontrollable bleeding from any site
- Blood in vomit or vomit that looks like coffee grounds
- Black or tarry stools, or bright red blood in stool
- Pink or brown urine
- Sudden severe headache, confusion, vision changes, or weakness on one side (signs of intracranial bleeding)
- Signs of allergic reaction: swelling of face, lips, tongue or throat, difficulty breathing, severe skin rash
In the ARISTOTLE trial, the overall discontinuation rate due to adverse events was similar between apixaban and warfarin. The favourable bleeding profile of apixaban, particularly the reduced rate of intracranial haemorrhage, is one of the key clinical advantages that has led to its widespread adoption. A meta-analysis published in The Lancet (Ruff et al., 2014) confirmed that DOACs as a class are associated with a 52% reduction in intracranial haemorrhage compared with warfarin.
How Should You Store Apixaban?
Quick Answer: Store apixaban tablets at room temperature (below 30°C / 86°F) in the original packaging. Keep out of reach of children. Do not use after the expiry date printed on the packaging.
Proper storage of medications is essential to maintain their effectiveness and safety. Apixaban tablets should be stored according to the following guidelines:
- Temperature: Store at room temperature, not exceeding 30°C (86°F). Do not freeze.
- Moisture: Store in the original blister packaging or bottle to protect from moisture. Do not transfer tablets to a different container unless it provides adequate protection.
- Light: No special precautions are required regarding light exposure.
- Children: Keep all medicines out of the sight and reach of children. Consider using a locked medicine cabinet.
- Expiry: Do not use apixaban after the expiry date stated on the carton and blister/bottle. The expiry date refers to the last day of that month.
- Disposal: Do not throw away medicines via household waste or wastewater. Ask your pharmacist how to dispose of medicines you no longer need. This will help protect the environment.
Apixaban tablets are available in blister packs or bottles. Once a bottle is opened, the tablets should be used within the period specified by the manufacturer (typically within 6 months for bottle presentations). Always check the packaging for specific storage instructions, as these may vary slightly between different generic manufacturers.
What Does Apixaban Contain?
Quick Answer: Each apixaban film-coated tablet contains either 2.5 mg or 5 mg of the active substance apixaban. The tablets also contain inactive ingredients (excipients) that help with manufacturing, stability, and absorption.
Understanding the composition of your medication can help identify potential allergens or excipients that may cause sensitivity. The composition may vary slightly between different manufacturers (originator vs. generic versions), but the active ingredient and its quantity remain the same.
Active Ingredient
- Apixaban 2.5 mg: Each film-coated tablet contains 2.5 mg apixaban.
- Apixaban 5 mg: Each film-coated tablet contains 5 mg apixaban.
Excipients (Inactive Ingredients)
The following excipients are typically present in apixaban film-coated tablets (based on the Eliquis formulation):
- Tablet core: Anhydrous lactose, microcrystalline cellulose (E460i), croscarmellose sodium (E468), sodium laurilsulfate, magnesium stearate (E470b).
- Film coating: Lactose monohydrate, hypromellose (E464), titanium dioxide (E171), triacetin (E1518), iron oxide yellow (E172) – in 2.5 mg tablets, or iron oxide red (E172) – in 5 mg tablets.
Apixaban tablets contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine. The amount of lactose in each tablet is small (approximately 40–80 mg per tablet depending on strength), and most patients with lactose intolerance can take apixaban without issues. However, patients with rare hereditary conditions of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
Tablet Appearance
- 2.5 mg tablets (Eliquis): Yellow, round, biconvex, debossed with “893” on one side and “2½” on the other side.
- 5 mg tablets (Eliquis): Pink, oval, biconvex, debossed with “894” on one side and “5” on the other side.
Generic versions may have a different appearance (shape, colour, markings) but contain the same active ingredient at the same strength.
Frequently Asked Questions About Apixaban
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation (ARISTOTLE). N Engl J Med. 2011;365(11):981–992. doi:10.1056/NEJMoa1107039
- Agnelli G, Buller HR, Cohen A, et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism (AMPLIFY). N Engl J Med. 2013;369(9):799–808. doi:10.1056/NEJMoa1302507
- Lassen MR, Gallus A, Raskob GE, et al. Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement (ADVANCE-3). N Engl J Med. 2010;363(26):2487–2498. doi:10.1056/NEJMoa1006885
- Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi:10.1016/S0140-6736(13)62343-0
- Van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968–1975.
- European Society of Cardiology. 2024 ESC/EACTS Guidelines for the Management of Atrial Fibrillation. Eur Heart J. 2024. doi:10.1093/eurheartj/ehae176
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation. J Am Coll Cardiol. 2019;74(1):104–132.
- European Medicines Agency. Eliquis (apixaban) – Summary of Product Characteristics. EMA, 2024. EMA – Eliquis
- U.S. Food and Drug Administration. Eliquis (apixaban) – Prescribing Information. FDA, 2024. FDA – Eliquis
- British National Formulary. Apixaban. BNF, 2025. BNF – Apixaban
- World Health Organization. WHO Model List of Essential Medicines – 23rd List. WHO, 2023.
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors (ANNEXA-4). N Engl J Med. 2019;380(14):1326–1335. doi:10.1056/NEJMoa1814051
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians specialising in clinical pharmacology, haematology, and internal medicine.
iMedic Medical Editorial Team – specialists in clinical pharmacology and anticoagulation therapy with extensive experience in evidence-based medical communication.
iMedic Medical Review Board – independent panel of medical experts who verify all content against current international guidelines (ESC, AHA/ACC, EMA, FDA, BNF, WHO).
All iMedic content follows the GRADE evidence framework and is based on Level 1A evidence (systematic reviews of randomised controlled trials) where available. We have no commercial funding or pharmaceutical sponsorship. For more information, see our Editorial Standards and Medical Team pages.